Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEMATIS: RG1662 in Down Syndrome
NCT02024789Phase 2Completed
- Sponsor
- Roche
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of basmisanil in Down syndrome (3 arms), sponsored by Roche. Primary endpoints: Repeatable Battery for the Assessment of Neuropsychological Status at 26 weeks, Vineland Adaptive Behavior Scales-II at 26 weeks and 1 more. Started May 2014; status: completed.
02
Drugs
basmisanil
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT02024789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024789.